Established in 2000, Affinium is a specialty pharmaceutical company with offices in Toronto and Austin. Affinium is developing a novel class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway and has built an international patent portfolio of more than 1,700 compounds, targets and assays in this new therapeutic class. The company’s lead clinical candidate, AFN-1252, is a small molecule antibiotic for both oral and IV treatment of staphylococcal infections, which has shown promising results in phase 1 clinical trials.
Contact Us
Venture Ontario
Suite 3001
250 Yonge St.
Toronto, ON M5B 2L7
